CJC-1295 and Ipamorelin: why researchers pair them
7 min read · Updated September 2026 · MY PEPTIDES Research Team
Key facts
In growth-hormone-axis work, the pairing researchers reach for most often is CJC-1295 with Ipamorelin. What makes the two worth running side by side is that they hit different receptors on the same pituitary cells: CJC-1295 is a GHRH (1-29) analog that switches on the GHRH receptor, whereas Ipamorelin is a selective agonist at the ghrelin, or GH-secretagogue, receptor (GHSR-1a), and notably it does not drive ACTH or cortisol. Because each peptide engages a separate receptor, putting both into one experimental system lets a lab weigh convergent against independent signaling and ask whether the downstream response comes out additive, synergistic, or simply unrelated under fixed exposure conditions. There is very little published research on the combination itself: the literature covers each peptide separately, so claims about the pairing are extrapolations rather than findings about the two together. Read-outs still track with concentration, timing, and how the model is built, and the questions are about receptor signaling rather than any physiological result. Each peptide ships as its own pre-mixed vial with a batch-specific Certificate of Analysis and is held refrigerated at 2-8°C. Both are supplied strictly for in-vitro laboratory research, never for human or veterinary use, have not been evaluated by the FDA, and carry no therapeutic claims. For US laboratories they ship cold-chain, tracked across the United States next business day, priced in US dollars.
One combination comes up again and again in growth-hormone-axis research: a GHRH analog paired with a growth-hormone secretagogue, two peptides that reach the same pituitary cells through different receptors. For that setup, CJC-1295 and Ipamorelin are the go-to pair, and the reason is mechanistic rather than a matter of marketing.
Research use only. Both peptides are supplied strictly for in-vitro laboratory research. They have not been evaluated by the FDA. This page says nothing about dosing, administration, or stacking for use, covers no human or animal application, and makes no therapeutic claims.
What each one is
The pairing only makes sense once you separate the two compounds and the receptors they act on:
- CJC-1295 is a GHRH (1-29) analog. It corresponds to the biologically active fragment of growth-hormone-releasing hormone, modified for stability, and it switches on the GHRH receptor. In research terms it is used as a probe for GHRH-receptor signaling.
- Ipamorelin is a selective agonist at the ghrelin, or GH-secretagogue, receptor (GHSR-1a). Its defining feature in the literature is selectivity: it engages GHSR-1a while leaving ACTH and cortisol pathways essentially untouched, which is what separates it from earlier, less clean secretagogues.
Two compounds, two receptors, one cell type. That is the whole premise of studying them together.
Different receptors, one system
Because CJC-1295 and Ipamorelin act on separate receptors expressed on the same pituitary cells, running them in a single experimental system is what lets a lab weigh convergent against independent signaling. The question is whether the downstream response turns out additive, synergistic, or simply unrelated once exposure conditions are fixed. Two peptides that both worked through the same receptor could not be used to ask that; the fact that they enter through different doors is precisely what makes the experiment informative.
As with any assay, what gets observed tracks with concentration, timing, and how the model is designed, and the work maps receptor signaling rather than any physiological outcome. The value of the pairing is that it holds two well-defined inputs against one readout.
Questions the pairing helps answer
- Where do GHRH-receptor and GHSR-1a signaling meet, or diverge, in pituitary-derived cells?
- Do second-messenger or transcriptional responses shift when both receptors are engaged at once, compared with either one alone?
- How does Ipamorelin's selectivity, barely touching ACTH or cortisol, shape a combined-signaling experiment against a broader secretagogue?
What the research actually examines
It is worth being honest about the evidence, because searches for this pairing return a great many confident claims. The published work sits on the two peptides separately: GHRH-receptor pharmacology on one side, GHSR-1a pharmacology on the other, largely in cell-based and preclinical models. There is very little primary research on the specific two-compound combination, so statements about what "CJC-1295 and Ipamorelin do together" are extrapolations from single-compound studies rather than findings about the pair.
That does not make the pairing uninteresting as a research setup. It means the research question, which is whether and where the two signaling routes interact, is a different thing from the marketing claim, which asserts a defined result. This guide stays with the former. Because a combined preparation cannot tell you which receptor produced an observed effect, careful protocols usually run each peptide on its own alongside the pair, which is one reason we supply CJC-1295 and Ipamorelin as separate vials rather than pre-blended.
Reading the certificates for a two-vial set
Because this is two vials rather than one blend, each arrives with its own batch-specific Certificate of Analysis, and each should be checked on its own terms:
- Per-vial identity and purity, confirmed by HPLC for purity and mass spectrometry for identity
- A batch reference on each certificate that matches the vial in front of you
- A date, since peptide material in solution is not indefinitely stable
The Certificate of Analysis guide explains how to read one, and recent certificates sit in our COA library. If you are working out concentrations from either vial, the peptide calculator handles the arithmetic.
How they ship in the United States
CJC-1295 and Ipamorelin arrive as two separate pre-mixed vials, each prepared under controlled conditions, HPLC-verified, and carrying its own Certificate of Analysis. Both peptides are synthesized in our own UK laboratory and then verified in a US laboratory before they ship, so the material an American researcher receives has been checked on both sides of the Atlantic. Orders are dispatched cold-chain from the warehouse that serves the United States, with tracked delivery across the country next business day, priced in US dollars and payable by Visa, Mastercard or Apple Pay. Store both vials refrigerated at 2-8°C on arrival, not frozen. The same two compounds also appear together in the Hulk Stack if you are looking at the wider growth-hormone-axis set.
What the pairing is not
- It is not an approved medicine. Neither peptide is approved in the United States, and neither has been evaluated by the FDA. Both are supplied for in-vitro laboratory research only.
- It is not a single blended product. It is two separately characterized vials, which is what keeps per-compound attribution possible.
- It is not a shortcut around single-compound work. A combined system shows whether the two signaling routes interact, not which one produced a given effect.
Dosing and administration
We do not publish dosing, reconstitution-for-use, administration, or "stacking" guidance for CJC-1295 and Ipamorelin. Both are supplied strictly for in-vitro laboratory research and are not for human or veterinary use, so quantity guidance aimed at a person would be inconsistent with what is actually supplied. Experimental concentrations are specific to the model and endpoint and belong in the primary literature.
Keep reading
CJC-1295
Available now from MY PEPTIDES — 99%+ purity, COA with every order, fast US shipping.
Frequently asked questions
- Why do researchers pair CJC-1295 with Ipamorelin?
- Because each works through a different receptor, the GHRH receptor for CJC-1295 and GHSR-1a for Ipamorelin, running both in the same model lets a lab compare convergent against independent signaling on the same pituitary cells. Both are supplied for in-vitro research use only.
- What is the difference between CJC-1295 and Ipamorelin?
- CJC-1295 is a GHRH (1-29) analog that activates the GHRH receptor. Ipamorelin is a selective agonist at the ghrelin, or GH-secretagogue, receptor (GHSR-1a) that notably does not drive ACTH or cortisol. They engage separate receptors, which is exactly why they are studied side by side.
- Is there research on the CJC-1295 plus Ipamorelin combination itself?
- Very little. The primary literature covers each peptide separately, largely in cell-based and preclinical models. Claims about the two working together are extrapolations from single-compound studies rather than findings about the pairing, which is why careful protocols run each vial on its own alongside the combination.
- Are CJC-1295 and Ipamorelin FDA-approved?
- No. Neither peptide is approved in the United States and neither has been evaluated by the FDA. They are supplied strictly for in-vitro laboratory research and are not for human or veterinary use.
- How do the two vials ship in the US, and do they need reconstituting?
- They ship as two separate pre-mixed solutions, each with its own batch-specific Certificate of Analysis, so there is no powder to reconstitute. Orders are dispatched cold-chain from the warehouse that serves the United States, with tracked delivery across the country next business day, priced in US dollars and payable by Visa, Mastercard or Apple Pay. Refrigerate both vials at 2-8°C on arrival and do not freeze them.